Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study

被引：0
|
作者：
von Amsberg, G. [1 ]
Powles, T. [2 ]
Loriot, Y. [3 ]
Ravaud, A. [4 ]
Vogelzang, N. J. [5 ]
Duran, I. [6 ]
Retz, M. [7 ]
De Giorgi, U. [8 ]
Oudard, S. [9 ]
Bamias, A. [10 ]
Koeppen, H. [11 ]
Leng, N. [11 ]
Kadel, E. E. [11 ]
Hegde, P. S. [11 ]
Cui, N. [11 ]
Shen, X. [11 ]
Green, M. [11 ]
Banchereau, R. [11 ]
Mariathasan, S. [11 ]
van der Heijden, M. S. [12 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Ctr Oncol, Hamburg, Germany
[2] Queen Mary Univ London, Barts Canc Inst, London, England
[3] Gustave Roussy, Villejuif, France
[4] Hop St Andre CHU, Bordeaux, France
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] Univ Seville, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio, CSIC, Seville, Spain
[7] Tech Univ Munich, Munich, Germany
[8] IRST IRCCS, Meldola, Italy
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Univ Athens, ALEXANDRA Hosp, Athens, Greece
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P990
引用
收藏
页码：325 / 326
页数：2
相关论文
共 42 条
  • [31] Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
    Bamias, Aristotelis
    Davis, Ian
    Galsky, Matthew
    Arranz, Jose a
    Kikuchi, Eiji
    Grande, Enrique
    Muro, Xavier Garcia del
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Schutz, Fabio A.
    Puente, Javier
    Li, Jian-Ri
    Panni, Stefano
    Gumus, Mahmut
    Ozguroglu, Mustafa
    Mariathasan, Sanjeev
    Poloz, Yekaterina
    Bene-Tchaleu, Fabiola
    Lee, Chooi
    Bernhard, Sandrine
    De Santis, Maria
    LANCET ONCOLOGY, 2024, 25 (01): : 46 - 61
  • [32] Overall survival (OS) by response during "induction" from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC).
    Grande, Enrique
    Bamias, Aristotelis
    Galsky, Matthew D.
    Kikuchi, Eiji
    Davis, Ian D.
    Arranz, Jose Angel
    Kalebasty, Arash Rezazadeh
    Del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    Shen, Xiaodong
    Ding, Beiying
    Zhu, Qian
    Linsenmeier, Jeremy
    De Santis, Maria
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
    Grande, Enrique
    Arranz, Jose A.
    De Santis, Maria
    Bamias, Aristotelis
    Kikuchi, Eiji
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Schutz, Fabio A.
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Kalebasty, Arash Rezazadeh
    Ye, Dingwei
    Mariathasan, Sanjeev
    Bene-Tchaleu, Fabioia
    Bernhard, Sandrine
    Lee, Chooi
    Davis, Ian
    Galsky, Matthew
    LANCET ONCOLOGY, 2024, 25 (01): : 29 - 45
  • [34] Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
    Loriot, Y.
    Matsubara, N.
    Huddart, R. A.
    Houede, N.
    Laguerre, B.
    Guadalupi, V.
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1201 - S1201
  • [35] EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
    Powles, Thomas
    van der Heijden, Michiel Simon
    Loriot, Yohann
    Bedke, Jens
    Valderrama, Begona P.
    Iyer, Gopa
    Kikuchi, Eiji
    Hoffman-Censits, Jeannie
    Vulsteke, Christof
    Drakaki, Alexandra
    Rausch, Steffen
    Arafat, Waddah
    Park, Se Hoon
    Swami, Umang
    Li, Jian-Ri
    Gorla, Seema Rao
    Homet Moreno, Blanca
    Yu, Xuesong
    Lu, Yi-Tsung
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [36] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [37] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [38] Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
    Peters, Solange
    Cho, Byoung Chul
    Reinmuth, Niels
    Lee, Ki Hyeong
    Luft, Alexander
    Ahn, Myung-Ju
    Baas, Paul
    Dols, Manuel Cobo
    Smolin, Alexey
    Vicente, David
    Moiseyenko, Vladimir
    Antonia, Scott J.
    Nakagawa, Kazuhiko
    Goldberg, Sarah B.
    Kim, Edward
    Raja, Rajiv
    Brohawn, Philip
    Clemett, Delyth
    Thiyagarajah, Piruntha
    Scheuring, Urban
    Liu, Feng
    Rizvi, Naiyer
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
    Dziadziuszko, R.
    Peters, S.
    Gadgeel, S. M.
    Mathisen, M. S.
    Shagan, S. M.
    Felip, E.
    Morabito, A.
    Cheema, P.
    Cobo Dols, M.
    Andric, Z.
    Barrios, C. H.
    Yamaguchi, M.
    Dansin, E.
    Danchaivijitr, P.
    Johnson, M.
    Novello, S.
    Gandara, D. R.
    Schleifman, E.
    Wang, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S950 - S951
  • [40] Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
    Barlesi, F.
    Ozguroglu, M.
    Vansteenkiste, J. F.
    Spigel, D.
    Yang, J. C-H.
    Bajars, M.
    Ruisi, M.
    Manitz, J.
    Park, K.
    ANNALS OF ONCOLOGY, 2019, 30
12345